key: cord-0073170-7aroji6m
authors: Ivanušec, Adrijan; Šribar, Jernej; Križaj, Igor
title: Secreted Phospholipases A(2) - not just Enzymes: Revisited
date: 2022-01-01
journal: Int J Biol Sci
DOI: 10.7150/ijbs.68093
sha: 6710fa5342bd6ae82b12d4a9195013579d2ace6b
doc_id: 73170
cord_uid: 7aroji6m

Secreted phospholipases A(2) (sPLA(2)s) participate in a very broad spectrum of biological processes through their enzymatic activity and as ligands for membrane and soluble receptors. The physiological roles of sPLA(2)s as enzymes have been very well described, while their functions as ligands are still poorly known. Since the last overview of sPLA(2)-binding proteins (sPLA(2)-BPs) 10 years ago, several important discoveries have occurred in this area. New and more sensitive analytical tools have enabled the discovery of additional sPLA(2)-BPs, which are presented and critically discussed here. The structural diversity of sPLA(2)-BPs reveals sPLA(2)s as very promiscuous proteins, and we offer some structural explanations for this nature that makes these proteins evolutionarily highly advantageous. Three areas of physiological engagement of sPLA(2)-BPs have appeared most clearly: cellular transport and signalling, and regulation of the enzymatic activity of sPLA(2)s. Due to the multifunctionality of sPLA(2)s, they appear to be exceptional pharmacological targets. We reveal the potential to exploit interactions of sPLA(2)s with other proteins in medical terms, for the development of original diagnostic and therapeutic procedures. We conclude this survey by suggesting the priority questions that need to be answered.

Secreted phospholipases A 2 (sPLA 2 s) (EC 3.1.1.4) are a structurally related group of low-molecularmass enzymes (14-18 kDa) that catalyse the hydrolysis of glycerophospholipids (phospholipids hereafter) at their sn-2 position, to produce lysophospholipids and free fatty acids. sPLA2s contain 6 to 8 disulphide bonds, a highly conserved His/Asp catalytic dyad, and a Ca 2+ -binding loop [1] . Several sPLA 2 isoforms have been described in mammals.

Depending on their structural characteristics, the mammalian sPLA 2 s are divided into 11 groups (G): IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA and XIIB [2] . Snake venom sPLA 2 s are orthologous to mammalian GIIA, GIIB or GIIE sPLA 2 s, or they belong to the unique GIA sPLA 2 s [3] . sPLA 2 s from bee and lizard venoms are homologous to mammalian GIII sPLA 2 s. Finally, the further GIX sPLA 2 s are found in venom of marine snails, and GXIA and GXIB sPLA 2 s are plant proteins.

The enzymatic activity of sPLA 2 s define their participation in a very broad spectrum of biological processes. Generally, sPLA 2 s are secreted from cells and require micromolar to millimolar Ca 2+ to be catalytically competent. They predominantly target phospholipids in the extracellular space, although they also act intracellularly. sPLA 2 s show distinct substrate specificities in terms of the phospholipid polar headgroups and the fatty acids esterified at the sn-2 position of the glycerol backbone. For instance, GIII, GV and GX sPLA 2 s efficiently hydrolyse phosphatidylcholine, while GIIA sPLA 2 has higher activity against negatively charged phospholipid substrates, and in particular, phosphatidylserine, phosphatidylglycerol and phosphatidylethanolamine. For their sn-2 fatty acid tail specificities, GIB, GIIA and GIIE sPLA 2 s are promiscuous. GV sPLA 2 preferentially targets sn-2 Ivyspring International Publisher fatty acyls with low number of double bonds, such as oleyl, while GIID, GIIF, GIII and GX sPLA 2 s target polyunsaturated fatty acyls, such as arachidonyl. sPLA 2 isoforms have unique tissue and cellular distributions, and therefore it is evident that individual sPLA 2 s have distinct enzyme-activityrelated biological functions. These include the generation of a variety of lipid mediators, along with membrane remodelling, modification of extracellular non-cellular phospholipid components of pulmonary surfactant, microparticles and lipoproteins, and degradation of microbial membranes and dietary phospholipids. The pathophysiological aspects of sPLA2s as enzymes have been comprehensively reviewed recently (e.g., [2, 4] ), and therefore we will not focus on these here. Instead, our attention here is focussed on sPLA 2 s acting as ligands, where fewer of the details have been described.

The existence of sPLA 2 s without enzymatic activity but with pharmacological activity was an early indication that sPLA 2 s can participate in physiological settings not just as enzymes, but also as ligands for membrane and soluble receptors. Indeed, in 1982, the first specific sPLA 2 -binding protein (sPLA 2 -BP) was discovered [5] . Since then, the number of newly characterized sPLA 2 -BPs has expanded considerably (Table 1) , and due to the development of more sensitive analytical methodologies, this process continues. Several reviews on sPLA 2 -BPs have been published over the years [6] [7] [8] [9] , although the most recent is 10 years old [9] . Therefore, now is an appropriate time to survey the advances in this important area of research, and to critically discuss new insights and suggest research directions.

There are two types of sPLA 2 -BPs: integral membrane proteins and soluble proteins [9] . The former belong to one of the following protein families: (1) muscle-type sPLA 2 receptors (M-type sPLA 2 Rs); (2) heparan sulphate proteoglycans (HSPGs); (3) integrins; (4) vascular endothelial growth factor receptors (VEGFRs); and (5) ion channels. Two new integral membrane sPLA 2 -BPs have been described recently, a G-protein-coupled receptor (GPCR), and cytochrome c oxidase (CCOX) [35, 37] . CCOX is the only known intracellular membrane sPLA 2 -BP, as all of the other integral membrane sPLA 2 -BPs are located in the plasma membrane. On the other hand, soluble sPLA 2 -BPs are more frequently found inside cells, in the endoplasmic reticulum (ER), cytosol or nucleus, as well as in the extracellular space. The ER-resident sPLA 2 -BPs, disulphide isomerase (PDI), taipoxin-associated 49-kDa Ca 2+ -binding protein (TCBP-49) and crocalbin, and the cytosolic calmodulin (CaM) and 14-3-3 proteins, have been known for some time. Two new soluble sPLA 2 -BPs were only described more recently: vimentin [26] and nucleolin [27] . Vimentin is an intermediate filament protein, as a constituent of the cytoskeleton, while nucleolin is a nucleolar protein; however, both of these proteins are also found on the cell surface, which is where they are most likely to interact with sPLA2s. Extracellular sPLA 2 -BPs include pentraxins, α-, β-and γ-type sPLA 2 inhibitors (PLIs), blood coagulation factors, pulmonary surfactant protein A (SP-A), metalloproteinase inhibitor DM64, and a serine protease inhibitor (C1 inhibitor protein). The main characteristics of the sPLA 2 -BPs are shown in Table 1 .

Structural aspects of sPLA 2 protein-binding-promiscuity sPLA 2 -BPs are structurally so diverse that attempts to define their common sPLA 2 -binding attributes have remained unsuccessful. To solve this problem, it would be most helpful to determine the three-dimensional structures of complexes between sPLA 2 s and the sPLA 2 -BPs, and thus to analyse their interaction areas. However, contemporary methodologies are still not optimal for this kind of approach.

The focus has thus mainly been on well-defined structural elements that are present in more than one type of sPLA 2 -BP, such as the C-type carbohydrate recognition domain (CRD) and CRD-like folds (in M-type sPLA 2 Rs, SP-A, α-PLIs), the EF-hand Ca 2+ -binding motif (in CaM, crocalbin, TCBP-49), and the immunoglobulin-like (Ig-like) domain (in VEGFRs, DM64) ( Figure 1 ).

Only the CRD fold ( Figure 1A ) has been confirmed as an sPLA 2 -binding structure [10] . Using radio-iodinated snake venom GIA sPLA 2 ( 125 I-OS 1 ), it was established that one of the eight CRDs in M-type sPLA 2 R (i.e., CRD5) includes the sPLA 2 binding site. This also revealed that not all of the CRDs can bind sPLA 2 s. M-type sPLA 2 R bound sPLA 2 s only under neutral and basic conditions, which implies that positively charged amino acids have important roles in this interaction. At pH 6 or lower, M-type sPLA 2 R also underwent conformational changes that prevented the binding of sPLA 2 s [41] . For the other two CRD-fold-containing sPLA 2 -BPs, as lung SP-A [13] and soluble α-PLIs from sera [12] , the sPLA 2 -binding characteristics are not very clear yet. As M-type sPLA 2 R and α-PLIs do not require Ca 2+ to bind sPLA 2 s [12, 42] , while SP-A does require Ca 2+ , this indicates that CRDs bind sPLA 2 s in different ways. To date, Ca 2+ -dependent binding of sPLA 2 s has been reported only in a case of a single CRD-containing sPLA 2 -BP, SP-A, while Ca 2+independent binding of sPLA 2 s has been shown for sPLA 2 -BPs with multiple CRDs, where more than one CRD constitutes the sPLA 2 -binding site. For M-type sPLA 2 R, three consecutive CRD repeats (repeats 4, 5, 6) were shown to influence sPLA 2 binding [10] , and consistently, in α-PLIs, the trimeric CRD proteins, the central part, where three CRDs are associated together, has been suggested to provide the sPLA 2 -binding site [43] . There are plenty of other CRD-containing proteins, such as the mannose receptor, Endo180, DEC205 and FcRY. At present, only the human mannose receptor has been demonstrated to interact with bee venom GIII sPLA 2 [44] , while FcRY did not bind any of the sPLA 2 s tested [45] .

To recognize sPLA 2 -binding attributes of sPLA 2 -BPs it is important to also consider the characteristics of the sites on sPLA 2 s that interact with sPLA 2 -BPs, as these are complementary to the sPLA 2 -binding sites on sPLA 2 -BPs. It has to be borne in mind, however, that a single sPLA 2 molecule might harbour multiple protein-binding sites [46] , and therefore it is reasonable to consider separately binding sites directed towards particular types of sPLA 2 -BPs, or those sPLA 2 s that induce the same interaction-dependent physiological effects.

The interaction of an sPLA 2 with a CRD fold is primarily governed by the structure of the interfacial binding surface (IBS) of the sPLA 2 [47] . The IBS is defined as the molecular surface with which sPLA 2 contacts a phospholipid membrane -its substrate. The IBS is formed by a collar of hydrophobic amino acids around the entrance to the catalytic site of the enzyme, and by mainly positively charged amino acids in more remote positions. The amino acids within or close to the Ca 2+ -binding loop in sPLA 2 s were also shown to be involved in the interactions between sPLA 2 s and CRDs [42] ; however, not profoundly, consistent with the evidence that the Ca 2+ -binding loop is highly conserved among sPLA 2 s that show considerably different affinities for M-type sPLA 2 R. sPLA 2 -BPs that contain Ig-like domains, such as VEGFRs and DM64, have been shown to associate with catalytically inactive myotoxic sPLA 2 s. VEGFRs are receptor tyrosine kinases, and they interact with sPLA 2 s through their extracellular region, which is composed of seven Ig-like domains. Although the interaction of myotoxic sPLA 2 s and VEGFRs has not been functionally linked with myotoxic effects yet, the C-terminal region of these sPLA 2 s (known as the 'myotoxic site') was shown to also be responsible for binding to VEGFRs [22, 23] . The myotoxic site of the snake venom myotoxic sPLA 2 s has been attributed to amino acids 115-129, which form a single α-helical turn at the C-terminus [48] [49] [50] . This C-terminal region is firmly attached to the body of the protein by two disulphide bonds, Cys27-Cys126 and Cys50-Cys133, thus constraining its position and orientation. The myotoxicity of sPLA 2 s has been associated with a cluster of positively charged amino acids in this region (i.e., conserved Lys115 and Arg118, and possibly also Lys122 and Lys127), and with hydrophobic amino acids at positions 121 and 125 [51, 52] .

The sPLA2-BP DM64 was originally isolated from marsupial (Didelphis marsupialis) blood, and it was shown to inhibit the myotoxic activity of several sPLA 2 s [24] . DM64 contains five Ig-like domains. Its myotoxicity-inhibitory activity is most likely due to its binding to the myotoxic site of sPLA 2 s, to thus obstruct their association with the 'myotoxicity receptor', which would be VEGFR. Contrary to what is seen for CRD in M-type sPLA 2 R, binding of sPLA 2 s to DM64 does not inhibit their enzymatic activity. This is in agreement with the involvement of the C-terminal of these sPLA 2 s in the interaction with this Ig-like domain-containing sPLA 2 -BP, rather than the IBS.

Identification of the PDZ-binding domain at the C-terminus of some myotoxic sPLA 2 s [53] suggested that there is another group of sPLA 2 -BPs, as PDZ-domain-containing proteins. In muscle cells, these proteins include, e.g., LDB3 and α-1-syntrophin [54, 55] ; however, their potential sPLA 2 binding remains to be tested.

The third type of well-defined structural element present in more than one sPLA 2 -BP is the EF-hand Ca 2+ -binding motif. These sPLA 2 -BPs include CaM, crocalbin and TCBP-49, although the structural aspects of sPLA 2 binding have been studied only for CaM. A three-dimensional model of a complex between CaM and the snake venom GIIA sPLA 2 ammodytoxin (Atx) [16] revealed that CaM 'clamps' Atx between its N-terminal and C-terminal domains ( Figure 2A ). Atx contacts CaM most extensively through a distinct patch of hydrophobic and charged amino acids at its C-terminus, which interact with the central part of CaM, and through the α-helices C and E, which contact the C-terminal globular domain of CaM. In the complex, Atx is oriented in such a way that the entrance to its enzymatic pocket remains open wide. In the complex, a new larger membranecontacting area (IBS) is formed; this comprises parts of both Atx and CaM, and explains the increased enzymatic activity of complexed Atx.

Considerable structural insight has also been gained for the interactions between the anticoagulant GIIA sPLA 2 s Atx, CB (basic sPLA 2 subunit of crotoxin, from venom of the South American rattlesnake [Crotalus durissus terrificus]) and daboxin P (from venom of the Indian viper [Daboia r. russelii]), and human activated blood coagulation factor X (FXa) [40, 56, 57, 58] . The interaction area between the anticoagulant sPLA 2 s and FXa is extensive, and encompasses the heavy and light chains of FXa. As evident from the model of the complex between Atx and FXa shown in Figure 2B , Atx interacts with the FXa heavy chain through its Ca 2+ -binding loop, α-helix C, β-wing, and C-terminal region, and with the FXa light chain through its β-wing and α-helices A and B. Electrostatic interactions importantly participate in the efficient binding of sPLA 2 s to FXa, including in particular some positively charged amino acids of Atx (e.g., Arg72, Lys74, His76, Arg77 in the β-wing; Arg118, Lys128, Lys127, Lys132 in the C-terminal region). However, not all of the basic sPLA2s are strong anticoagulants, which are consistent with the importance also of certain hydrophobic and aromatic sPLA 2 amino acids for optimal interactions with FXa (e.g., Atx: Phe124 in the C-terminal region; CB a2 : Trp70 in the 65-72 loop).

Molecular docking allowed to propose a model of the complex between ΔF508-NBD1 (nucleotidebinding domain 1), the sPLA 2 -binding domain of ΔF508CFTR (Phe508 deletion mutant of cystic fibrosis transmembrane conductance regulator), and CB b ( Figure 2C ) [33] . From the model, which applies also to the wild type NBD1 (i.e. CFTR), it can be seen that the binding interface of CB with ΔF508NBD1/NBD1 is predominately composed of the hydrophobic residues located in its α-helices A and B, Ca 2+ -binding loop and the C-terminal region. Hydrophobic interactions are clearly very important for holding both proteins together, nevertheless, also some polar amino acid residues are involved in the interaction. Forming ionic contacts with ΔF508NBD1/NBD1 of ΔF508CFTR/CFTR, the N-terminal His1 and the Asp112 in the C-terminal region of CB are two examples.

A three-dimensional model of the complex between Atx and PDI has also been reported [20] . PDI consists of multiple domains (i.e., a, a', b, b'), and according to the model shown in Figure 2D , the Atx-binding site on PDI is situated between domains b and b'. Atx interacts with PDI across an extensive area that also includes the Atx IBS. The basic amino acids are important for Atx binding to PDI, especially Arg77 and Arg118, but also Lys69, Arg72, Lys74 and Lys86. However, Atx also contacts PDI with some hydrophobic amino acids, Leu3, Leu19 and Phe24, and through two polar amino acids, Asn17 and Asn119.

Molecular docking has also provided some structural insights into the interactions between vurtoxin, another snake venom GIIA sPLA 2 , and the nicotinic acetylcholine receptor (nAChR) [59] . According to their model, vurtoxin binds at the interface of the α and γ subunits of nAChR, and is oriented with its active site towards the lipid bilayer ( Figure 2E ). Vurtoxin does not occupy the nAChR binding sites for its classical agonists and competitive antagonists; however, it is located very close to these.

Several structural features allow the sPLA2s to bind to structurally very diverse targets (Table 1 ; Figure 2 ), which is characteristic of promiscuous proteins [60, 61] . Despite the generally compact structure of sPLA 2 s, the flexibility of the exposed side chains of the amino acids at the IBS promotes their optimal binding to phospholipid aggregates, as their substrates, for efficient hydrolysis [62] . As indicated above, the IBS is critically involved also in the interactions of sPLA2s with the CRD-containing sPLA 2 -BPs and FXa, as also for PDI [20] and vimentin [26] . The association of the sPLA 2 IBS with a variety of different protein surfaces is most likely driven by the same principles as the association of the sPLA 2 IBS with phospholipid membranes. The flexibility of the sPLA 2 β-wing might be another feature that favours their high adaptability for different protein partners. For example, the β-wing of sPLA 2 s should be involved in the interactions of sPLA 2 s with β-PLIs and γ-PLIs [63] . sPLA 2 s are also characterized by patches of basic and hydrophobic amino acids that might also greatly broaden the spectrum of their protein interaction partners. We have already shown that such patches are part of the IBS, but they are also located in other parts of sPLA2s. Indeed, those at the C-terminus [62] are implicated in the binding of sPLA 2 s to CaM and VEGFR.

However, only the atomic structure of an sPLA 2 -sPLA 2 -BP complex will fully disclose the structural requirements for particular association. The present-day rapid advances in techniques for the determination of the three-dimensional structures of proteins might enable this in the near future; e.g., cryo-electron microscopy.

The structural diversity of sPLA 2 -BPs is consistent with the wide range of pathophysiological activities that have been associated with sPLA 2 s. By binding to sPLA 2 -BPs, sPLA 2 s have been suggested to be involved in inflammation [64, 65] , hormone release [66, 67] , neurotoxicity [20, 37, 68, 69] and myotoxicity [22] . It has already been confirmed that sPLA 2 s are ligands for specific sPLA 2 -BPs in cytokine production [70] , cell proliferation [71] [72] [73] , cell migration [74] , lipid mediator production [75] , antibacterial activity [73] and blood coagulation [40] . These (patho)physiological effects of sPLA 2 s might arise through: (1) specific cellular translocation and associated actions of sPLA 2 s after their binding to sPLA 2 -BPs; (2) triggering of specific signalling following their binding to sPLA 2 -BPs; and/or (3) regulation of sPLA 2 enzymatic activity by sPLA 2 -BPs ( Figure 3 ). Particular mechanistic possibilities for sPLA 2 actions as ligands for sPLA 2 -BPs are exemplified and discussed below.

Binding of sPLA 2 s to some sPLA 2 -BPs does not have any obvious physiological function. Some functional implications of sPLA 2 s acting as ligands certainly remain to be discovered, while others might be latent. When environmental conditions change radically, these interactions might become functional. Promiscuous proteins, which include sPLA 2 s, can acquire new functions much more readily than non-promiscuous proteins, which can provide swifter adaptation of the organism to new situations [76, 77] . In each of these compartments, they can act as enzymes or ligands for receptors, or they can undergo proteolytic degradation in the lysosome. (B) As ligands for receptors, sPLA2s have been specifically implicated in molecular signalling through decreased (1) or increased (2) permeabilities of certain ion channels, inhibition (3) or activation (4) of activities of receptor tyrosine kinases, modulation of activities of GPCR (5), interference in integrin-mediated functions (6), attenuation of ATP production (7) and inhibition of blood coagulation, at different stages (8, 9, 10) . (C) Binding of sPLA2 to a sPLA2-BP might inhibit or potentiate phospholipolytic activity. The Figure was created with BioRender.com.

Although sPLA 2 s appear to be secreted into the extracellular space after being synthesized inside the cell, convincing evidence of their intracellular localization and activities has already been provided [69, 71, 78, 79] . sPLA 2 s can re-enter cells after their synthesis and secretion, to pass into the cytosol and to different organelles, such as the nucleus and mitochondria [80] . Indeed, several sPLA 2 -BPs have been suggested to assist sPLA 2 s in their retrograde cellular transport and intracellular translocation ( Figure 3A) .

The sPLA 2 -BP in the lumen of the ER, PDI, has been proposed to be involved in such retro-transport of the Atx snake venom GIIA sPLA 2 , which is a neurotoxin from nose-horned viper venom that acts presynaptically [20] . Molecular docking and heterologous competition assays have suggested that PDI acts in a similar way as on Atx also on some mammalian sPLA2s, such as GIB, GIIA and GV sPLA 2 s. Two other candidates for the same function are the ER luminal proteins TCBP-49 and crocalbin, which were discovered through their binding to the hetero-oligomeric snake venom sPLA 2 s taipoxin and crotoxin [9] . As for PDI, these two EF-hand Ca 2+ -binding proteins have the characteristic ER-retention motif at their C-termini, which has been suggested to be essential for retention and concentration of sPLA 2 s in the ER before they are translocated into the cytosol. Some other EF-hand Ca 2+ -binding proteins might also interact with sPLA 2 s. For instance, the Miro proteins are mitochondrial adaptor proteins that promote the transportation of mitochondria by connecting them to motor proteins [81] . Binding of sPLA 2 s to the Miro proteins might concentrate the sPLA 2 s on the outer mitochondrial membrane, which would explain their colocalization with mitochondria after entering cells [78, 79] .

Cellular retro-transport of sPLA 2 s might also be associated with two recently discovered sPLA 2 -BPs, vimentin and nucleolin. Vimentin belongs to the family of intermediate filaments, although it is also present on the cell surface and in extracellular fluids. Indeed, in recent years, vimentin has been shown to have a much wider role in cell physiology, rather than just being an inert scaffold protein [82] . Vimentin was identified as the receptor for GIIA sPLA2 on the surface of apoptotic human T lymphocytes [65] . Interactions between these two proteins was also shown in rheumatoid fibroblast-like synoviocytes, which associated rapid internalization of sPLA 2 with arachidonic acid metabolism in synovial inflammation [83] . Recently, vimentin was reported to bind an acidic sPLA 2 (NnPLA 2 -I) from venom of the Indian cobra (Naja naja) [26] . Binding of NnPLA 2 -I to vimentin resulted in its internalization into partially differentiated myoblasts. The involvement of vimentin in cellular uptake mechanisms has already been shown for C3, a Clostridium botulinum toxin [84, 85] , and several viruses, such as human immunodeficiency virus type 1, vaccinia virus and the severe acute respiratory syndrome coronavirus [86] . In all of these cases, vimentin acts as a component of the cellular attachment mechanism, either as a receptor or a co-receptor. In a similar way, vimentin might mediate internalization of sPLA2s. This is further supported by the similar location of the binding sites on vimentin for dengue virus DENV-2 envelope protein domain III, Clostridium botulinum C3 exoenzyme and NnPLA 2 -I, all of which have been proposed to bind to the rod domain of vimentin [26, 84, 87] .

Nucleolin was described recently as an sPLA 2 -BP due to its binding to the myotoxin MT-II, a Lys49 sPLA 2 from venom of a pit viper, the terciopelo (Bothrops asper) [27] . It appears most likely that nucleolin participates in the toxic mechanism of MT-II through promotion of its translocation from the outside into the perinuclear and nuclear areas of myotubes and macrophages. Nucleolin was previously reported to mediate the internalization of several other molecules from the cell surface to the nucleus through an active Ca 2+ -dependent transport mechanism [88] , which might also be the mechanism for sPLA 2 internalization. It would be interesting to investigate the potential involvement of nucleolin in GV sPLA 2 translocation to the nucleus, where this sPLA 2 has been shown to act on the nuclear envelope [89] . Nucleolin has been shown to act as a chaperone for histones and TDP-43 [90, 91] , so it might also stabilize sPLA 2 s in the reducing environment of the cytosol.

Neuronal pentraxins (i.e., NP1, NP2/Narp) are sPLA 2 -BPs that are homologous to acute phase proteins, and these might also function in retrograde transport of sPLA 2 s from the cell surface [28, 92] . An sPLA 2 -shuttling function has also been suggested for the ubiquitously expressed eukaryotic cytosolic 14-3-3 proteins, which were discovered through their interactions with Atx [29] . The neurotoxicity of Atx also involves its binding to the 14-3-3γ and 14-3-3ε isoforms, to correctly position it at the plasma membrane to hinder the function of amphiphysin, and thus of vesicle endocytosis [69] .

HSPGs such as the GPI-anchored glypican I, biglycan, syndecan and perlecan, can bind mammalian sPLA 2 s, e.g. GIIA, GIID and GV sPLA 2 s. Using transfected human embryonic kidney 293 cells, it was shown that a GPI-anchored HSPG facilitated the shuttling of GIIA sPLA 2 into certain subcellular compartments where the sPLA 2 then released arachidonic acid for prostaglandin synthesis [93] . Binding of human GIIA sPLA 2 to HSPGs was further demonstrated in human primary T-lymphocytes [25] . Recently, it was suggested that GIIA sPLA 2 can increase endothelial cell permeability after binding to HSPGs on the surface of these cells, in a process that is dependent on the sPLA 2 phospholipase activity [39] . In a similar way, HSPGs might be receptors for heparin-binding snake venom sPLA 2 s. By binding to HSPGs, these toxins might enhance inflammation and permeability of the endothelium, to allow the venom to spread more efficiently in the tissue.

M-type sPLA 2 R can rapidly internalize sPLA 2 s and direct them to the lysosomes, where they are then degraded [94, 95] . In this way, M-type sPLA 2 R can down-regulate the activity of sPLA 2 s. M-type sPLA 2 R can also mediate sPLA 2 signalling by transporting sPLA 2 s into specific intracellular compartments [96, 97] . Recent structural studies of the human M-type sPLA 2 R ectodomain using cryo-electron microscopy showed pH-dependent conformational changes that might have important roles in the control of the functional properties of this receptor, including its sPLA 2 binding [41] .

As proteins that are secreted into the extracellular space, sPLA 2 s encounter various plasma-membrane receptors on target cells. By binding to some of these receptors, sPLA 2 s can induce intracellular responses that are associated with different physiological processes, such as vascular permeability, cell growth, migration and senescence, hormone release, cytokine and NO production, inflammation, cell adhesion and angiogenicity ( Figure  3B ).

In this context, sPLA2s have been reported to interact with different ion channels (K + , Na + or Ca 2+ ). β-Butx is a neurotoxic sPLA 2 from venom of the many-banded krait (Bungarus multicinctus), and it has been shown to interact with voltage-dependent K + channels. Further, MitTx from venom of the Texas coral snake (Micrurus t. tener) was shown to bind to voltage-insensitive Na + -conducting acid-sensing ion channels [98] . However, both of these toxins are heterodimers that are composed of the sPLA 2 subunit and a subunit homologous to the Kunitz-type serine protease inhibitor and, with the ion channel binding attributed to the latter. Therefore, these ion channels are not sPLA 2 -BPs. Nonetheless, the neurotoxicity with β-Butx and the pain with MitTx did not occur in the absence of the sPLA 2 subunit. Some sPLA 2 s can influence the conductance of Ca 2+ channels, the N-methyl-D-aspartate receptor or L-type voltage-dependent Ca 2+ channels. Direct binding of sPLA 2 s to these channels has, however, not been demonstrated to date [30, 99] .

Recently, pentameric ligand-gated ion channels, nAChRs [31, 59] and their bacterial homologue GLIC from the cyanobacterium Gloeobacter violaceus [32] , were reported to be sPLA2-BPs. By binding to nAChRs, sPLA 2 s might affect nAChR-related functions, such as neuromuscular transmission and cell proliferation. Interestingly, nAChRs have also been described for the outer mitochondrial membrane, and were associated with regulation of the formation of mitochondrial permeability transition pores, which release pro-apoptotic substances like cytochrome c and reactive oxygen species [100] .

Antagonists of nAChR were shown to attenuate the release of cytochrome c. The antagonistic effect of certain sPLA2s on some nAChRs subtypes might therefore link these sPLA 2 s to control of cellular viability through these nAChRs [31, 101] .

CFTR is a Clchannel that was defined as an sPLA 2 -BP using CB, the basic sPLA 2 subunit of crotoxin [33] . CB was shown to bind and allosterically potentiate the activity of CFTR. Of a very high medical significance, CB was found to bind with nanomolar affinity also to ΔF508CFTR mutant, the causative factor of cystic fibrosis, thus augmenting its activity. Importantly, by binding to ΔF508CFTR, CB acts also as a corrector, facilitating trafficking and delivery of the abnormal protein to the plasma membrane.

VEGFRs are receptor tyrosine kinases that can interact with some myotoxic snake venom sPLA2s. Although some of these toxins are potent antagonists of VEGFRs, it is still not clear whether their binding to VEGFRs is directly involved in their sPLA 2 myotoxicity [22, 23] . Nevertheless, the interactions between snake venom sPLA 2 s and VEGFRs might be important to enhance vascular permeability, to facilitate penetration of the snake venoms into tissues.

Epidermal growth factor receptor (EGFR) is another receptor tyrosine kinase that interacts with sPLA2s. It was reported to interact with human GIIA sPLA 2 [34] . However, in this case, the sPLA 2 acted as an agonist, as it up-regulated HER (human EGFR)/HER2-elicited signalling in lung cancer, thus stimulating cancer cell growth.

M-type sPLA 2 R has already been mentioned as an sPLA 2 -translocator (see section 4), and it can also act as a signalling receptor to transduce sPLA 2 -dependent signals independent of sPLA 2 catalytic activity. Through M-type sPLA 2 R, sPLA 2 s have been implicated in cell proliferation, migration and senescence, and in hormone release and cytokine and NO production. It was also suggested that human GIB sPLA 2 can induce kidney glomerular podocyte apoptosis via M-type sPLA 2 R [102] .

PA2-Vb is an acidic sPLA 2 from venom of the Chinese green tree viper (Trimeresurus stejnegeri), and it was shown to induce mouse aorta contraction independent of its enzymatic activity, by acting on a protease-activated receptor (PAR-1), which is a GPCR [35] . GPCRs are the largest and most diverse class of membrane receptors in eukaryotes, and their primary function is to transduce extracellular stimuli into intracellular signals, which lead to different cell responses.

Integrins are extracellular plasma membrane (transmembrane) proteins that are responsible for cell adhesion to the extracellular matrix. They are dimers, as combinations of one of 18 α-subunits and one of 8 β-subunits. Integrins αvβ3 and α 4 β 1 have been shown to bind mammalian GIIA sPLA 2 , while an acidic GIIA sPLA 2 from venom of the viper Macrovipera lebetina transmediterranea was shown to interact with integrins α 5 β 1 , α v β 3 and α v β 6 , to induce inflammation and inhibition of cell adhesion and migration and angiogenicity [36, 103] .

CCOX is an essential constituent of the respiratory chain complex, and was characterized as an sPLA2-BP due to its binding to Atx [37] . Through binding to subunit II, Atx was shown to inhibit the oxidase activity of CCOX, independent of its phospholipase activity. This might explain the inhibition of ATP production in nerve endings poisoned by the snake venom neurotoxic sPLA2s [104] . These findings also provide novel indications for the potential functions and malfunctions of the orthologous mammalian GIIA sPLA 2 in mitochondria. The blood coagulation system consists of a strictly regulated proteolytic cascade of blood coagulation factors that convey signals downstream to fibrinogen, which is then transformed into the insoluble fibrin network, and to activate platelets. Ultimately, a blood clot is formed to prevent blood loss from the injured blood vessel [105] . Several sPLA2s can affect this process by binding to one of these coagulation factors, to thus inhibit their functions ( Figure 3B ). Some snake venom sPLA 2 s bind to FX, or to its activated form FXa, or to thrombin (FIIa); e.g., crotoxin and Atx can induce anticoagulant effects through binding to FXa, to thus prevent formation of the prothrombinase complex [40, 106] . Human GIIA sPLA 2 acts on blood coagulation in exactly the same way [107] . Daboxin is an anticoagulant sPLA 2 that can bind to both FXa and FX [57] . On the other hand, Nk-PLA 2 α and Nk-PLA 2 β from venom of the monocled cobra (Naja kaouthia) act as anticoagulants through their binding to thrombin and their consequent inhibition of its proteolytic activity [108] .

Regulation of sPLA 2 enzymatic activity by sPLA 2 -BPs sPLA 2 s participate in many important physiological processes through their enzymatic activity [2] . These range from those dependent on the composition and flexibility of biological membranes, to those regulated by the products of the sPLA 2 phospholipolytic activity, which include lysophospholipids, free fatty acids and their metabolites -the whole range of signalling hormones [109, 110] . Regulation of the enzymatic activity of sPLA 2 s is thus extremely important for the correct functioning of an organism, and this regulation is also mediated through the binding of sPLA 2 s to particular sPLA 2 -BPs ( Figure 3C ).

M-type sPLA 2 R has been shown to regulate the activity of sPLA 2 s in two ways: through acting as an sPLA 2 inhibitor; and through mediating sPLA 2 endocytosis, which leads to sPLA 2 degradation in lysosomes [111] . Soluble form of M-type sPLA 2 R that is detected in the blood can function only in the first way [8] . Pulmonary SP-A is structurally and functionally similar to the soluble form of M-type sPLA 2 R. SP-A belongs to the CRD-containing family of proteins, and it inhibits the enzymatic activity of GIIA and GX sPLA 2 s in pulmonary surfactant [9] .

Soluble proteins that inhibit sPLA 2 s have been isolated from the blood of snakes and some other animals. These are ecologically connected with venomous snakes, and are known as the α-PLIs, β-PLIs and γ-PLIs [9] . sPLA2 inhibitors have also been found in plants. Withania somnifera glycoprotein (WSG) is an acidic glycoprotein that is similar to the α-chain of the γ-PLIs, and it was isolated from the medicinal plant known variously as Ashwagandha, Indian ginseng and winter cherry. WSG inhibits the enzymatic activity and toxicity of NN-XIa-PLA2, an sPLA 2 myotoxin from venom of the Indian cobra [112] [113] [114] .

Interestingly, sPLA 2 -BPs have also been shown to increase the enzymatic activity of sPLA 2 s. One such sPLA 2 -BP is the EF-hand Ca 2+ -binding intracellular protein CaM. When sPLA 2 s are in a complex with CaM, they also become more resistant to chemical denaturation [16, 17] . Two other sPLA 2 -BPs that can potentiate the catalytic activity of sPLA 2 s are vimentin [65] and GLIC [32] . The potentiating effect appears to occur because the interactions with these three sPLA 2 -BPs position the complexed sPLA 2 on the membrane in a way that provides more efficient catalytic function.

sPLA 2 -BPs have diverse physiological functions, and therefore their interactions with sPLA 2 s can be insightful and potentially helpful for medical applications. Important roles of M-type sPLA 2 R in cancers have been outlined recently, with a tumour suppressive role demonstrated [74, 115] . As ligands of M-type sPLA 2 R, sPLA 2 s can be used to study or to regulate processes in which M-type sPLA 2 R is involved. By binding to M-type sPLA 2 R, sPLA 2 s have already been indicated to have roles in cell proliferation, migration and senescence, hormone release, and cytokine and NO production. sPLA 2 s were also demonstrated to induce kidney glomerular podocyte apoptosis via M-type sPLA 2 R [102] . A recently generated conditional transgenic mouse that expresses human M-type sPLA 2 R1 will certainly facilitate future investigations into this sPLA 2 -BP under different pathophysiological conditions [116] .

VEGFRs are sPLA 2 -BPs that have also been shown to be involved in cancer development. By binding to VEGFRs, sPLA 2 s might inhibit angiogenesis, which is an essential process for cancer metastasis formation [117] . Therefore, the use of sPLA 2 s in chemotherapy has been proposed. In addition, the angiogenic pathways of VEGFRs and endothelial nAChRs have been shown to have cross-talk, which suggests that as antagonists of nAChRs, sPLA 2 s might further inhibit angiogenesis in this way [31, 118] . In contrast to the antagonistic effects on VEGFRs and nAChRs, GIIA sPLA 2 can activate EGFRs in lung cancer cells [34] . This leads to elevated HER /HER2-elicited signalling, which contributes to overexpression of GIIA sPLA 2 . Plasma concentration of GIIA sPLA 2 might therefore serve as a biomarker for lung cancer, and GIIA sPLA 2 might represent a therapeutic target to treat patients with lung cancer.

The integrin binding of snake venom sPLA 2 s has also been exploited for development of new anti-cancer agents that target cell proliferation and migration [36, 103] . MT-II binding to nucleolin appears to explain the higher toxicity of MT-II against cancer cells, as nucleolin is more abundant on the surface of cancer cells than of normal cells [90] . Nucleolin also participates in internalization of many viruses, which suggested that the anti-viral activity of some sPLA2s might be due to their nucleolin binding [27] .

The involvement of GIIA sPLA 2 in synovial inflammation through liberation of arachidonic acid for production of inflammatory eicosanoids has long been known. Efforts have been made to develop inhibitors of GIIA sPLA 2 to attenuate rheumatoid arthritis and sepsis, but without substantial success so far [119, 120] . Colocalization of GIIA sPLA 2 and vimentin is, however, associated with phospholipase-activity-independent mechanisms of signalling through arachidonic acid metabolism [83] , which provides the way for targeted studies of GIIA sPLA2 signalling, and for the development of new therapeutic strategies based on inhibition of GIIA sPLA 2 . Lee et al. (2013) [83] also identified vimentin as an interesting player in some other diseases where the involvement of GIIA sPLA 2 has been indicated, and particularly in cancers. GIIA sPLA 2 is overexpressed in many types of cancers, while vimentin is one of the signature biomarkers of tumour dedifferentiation through epithelial-mesenchymal transition [121, 122] .

Abundant expression of vimentin has also been observed in adult neurons as a response to injury, such as in Alzheimer's disease [123] . As vimentin might assist the internalization of GIIA sPLA2 into neurons, this suggests why GIIA sPLA 2 is involved in the aetiology of Alzheimer's disease. GIIA sPLA 2 might directly damage neurons or boost inflammation by releasing excessive arachidonic acid. Targeting of vimentin is, therefore, potentially interesting as a new therapeutic approach to treat patients with Alzheimer's disease.

A phospholipase-activity-independent mode of action is also characteristic for snake venom catalytically inactive sPLA2s. These can induce inflammation [124] ; e.g., MT-II can stimulate the production and release of inflammatory mediators, such as interleukin-6 [125] , interleukin-1, tumour necrosis factor α, leukotriene B4, thromboxane A2 and prostaglandins E2 and D2 [126] [127] [128] [129] . Indeed, this activity of MT-II was recently used to establish a new experimental model of acute arthritis [130] .

Mammalian GIB, GIIA, GV and GX sPLA2s induce the production of pro-inflammatory cytokines and chemokines, whereby these sPLA 2 s increase inflammation after binding to HSPGs or to M-type sPLA 2 R on macrophages, neutrophils, eosinophils, monocytes and endothelial cells [131] . This binding to HSPGs also participates in clearance of these sPLA 2 s and in reduction of their enzymatic activity towards low-density lipoprotein, which is an important factor in atherosclerosis [3, 132] . sPLA 2 s also mediate pro-inflammatory actions via integrins, as binding of GIIA sPLA 2 to human integrins α v β 3 , α 4 β 1 and α 5 β 1 trigger signalling that leads to inflammation [36, 133] . The effects of sPLA 2 s on haemostasis have great potential for medical applications as well. The induction of vasoconstriction by PA2-Vb binding to PAR-1 makes PA2-Vb interesting for the development of new therapeutic approaches against hypertension, atherosclerosis and diabetes-related vascular problems [35] . Moreover, snake venom sPLA 2 s can induce strong anticoagulant effects through competitive binding to constituents of the prothrombinase complex, which suggests their great potential for the development of therapeutic procedures to attenuate or prevent blood-clot formation [108] .

As already mentioned, GIIA sPLA2 has been associated with the aetiology of some neurodegenerative diseases, such as Alzheimer's disease [134] [135] [136] [137] . A hallmark of the induction of Alzheimer's disease is the elevated expression of GIIA sPLA2 in the affected tissue, with concomitant dysfunction of the neuronal mitochondria. As the pathological effects of presynaptically neurotoxic sPLA 2 s from snake venoms and GIIA sPLA 2 on mitochondria are similar, a description of the mode by which neurotoxic sPLA 2 s encounter and affect neuronal mitochondria at the molecular level is expected to advance the study of the role of endogenous GIIA sPLA 2 in this and other related destructive diseases.

These findings indicate a way to the development of original diagnostic and therapeutic solutions. An important breakthrough in this direction was the recent identification of CCOX as the mitochondrial receptor for Atx [37] . Application-wise, a very promising discovery was also the binding of crotoxin to ΔF508CFTR, responsible for cystic fibrosis. The sPLA 2 subunit of crotoxin has been used as a template to develop a new line of anti-cystic fibrosis agents [33] .

As well as participating in a very broad spectrum of biological processes through their enzymatic activity, sPLA 2 s participate in many physiological settings as ligands for membrane or soluble receptors. As new and more sensitive analytical tools are developed, the number of newly discovered sPLA 2 -BPs is growing. Further technical advances will promote the discovery of even more sPLA 2 -BPs. sPLA 2 -BPs are structurally diverse integral membrane and soluble proteins. Despite many attempts, their common sPLA 2 -binding attributes remain largely obscure. The solution to this puzzle will enable targeted searches of additional sPLA 2 -BPs. A straightforward approach to solve this problem would be the determination of the three-dimensional structures of complexes between sPLA 2 s and their sPLA 2 -BPs. With the development of powerful new technologies, such as cryo-electron microscopy, this is becoming more and more realistic. sPLA 2 s are very useful molecules from the evolutionary point of view. Particular structural features have made the sPLA 2 s promiscuous, and promiscuous proteins can acquire new functions more readily than other proteins. In this way, these can enable organisms to adapt more successfully to environmental changes.

Finally, due to their enzymatic activity and extensive interactomes, sPLA2s are exceptional pharmacological targets. Detailed descriptions of their actions at the molecular level will initiate the development of a plethora of original diagnostic and therapeutic approaches.

Atx: sPLA 2 from Vipera a. ammodytes venom; CaM: calmodulin; CB: basic sPLA 2 subunit of crotoxin; CCOX: cytochrome c oxidase; CFTR: cystic fibrosis transmembrane conductance regulator; CRD: carbohydrate recognition domain; DM64: metalloproteinase inhibitor from Didelphis marsupialis blood; ECD: extracellular domain; EGF(R): epidermal growth factor (receptor); ER: endoplasmic reticulum; FX/FXa/FIIa: blood coagulation factors; GLIC: proton-gated ion channel from Gloeobacter violaceus; GPCR: G-protein-coupled receptor; HER: human EGFR; hGIIA: human group IIA sPLA2; HSPGs: heparan sulphate proteoglycans; IBS: interfacial binding surface; Ig-like: immunoglobulin-like; M-type sPLA 2 Rs: muscle-type sPLA 2 receptors; nAChR: nicotinic acetylcholine receptor; NBD: nucleotidebinding domain; NP: neuronal pentraxin; OS 1 : sPLA 2 from Oxyuranus s. scutellatus venom; PAR: protease-activated receptor; PDI: protein disulphide isomerase; PLIs: sPLA 2 inhibitors; SP-A: pulmonary surfactant protein A; sPLA 2 : secreted phospholipase A 2 ; sPLA 2 -BP: sPLA 2 -binding protein; TCBP-49: taipoxin-associated 49-kDa Ca 2+ -binding protein; VEGFR: vascular endothelial growth factor receptor; WSG: Withania somnifera glycoprotein.

Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention

Updating phospholipase A2 biology

Snake Venom Phospholipase A2 Toxins

Novel functions of phospholipase A2 s: Overview

Binding of β-bungarotoxin to synaptic membrane fractions of chick brain

Receptors for a growing family of secreted phospholipases A2. Trends in pharmacological sciences

Increasing molecular diversity of secreted phospholipases A2 and their receptors and binding proteins

Phospholipase A2 receptor: A regulator of biological functions of secretory phospholipase A2

Secreted phospholipases A2 -Not just enzymes

Identification of the binding domain for secretory phospholipases A2 on their M-type 180-kDa membrane receptor

Identification and purification of a very high affinity binding protein for toxic phospholipases A2 in skeletal muscle

Alpha-type phospholipase A2 inhibitors from snake blood

The emerging roles of surfactant protein-A in asthma

Fortes-Dias CL. Endogenous phospholipase A2 inhibitors in snakes: a brief overview. The journal of venomous animals and toxins including tropical diseases

Insights on the structure of native CNF, an endogenous phospholipase A2 inhibitor from Crotalus durissus terrificus, the South American rattlesnake

Structural basis of the significant calmodulin-induced increase in the enzymatic activity of secreted phospholipases A2

Calmodulin is a nonessential activator of secretory phospholipase A2

Novel reticular calcium binding protein is purified on taipoxin columns

Crocalbin: A new calcium-binding protein that is also a binding protein for crotoxin, a neurotoxic phospholipase A2

On the role of protein disulfide isomerase in the retrograde cell transport of secreted phospholipases A2

Protein disulphide isomerase binds ammodytoxin strongly: possible implications for toxin trafficking

Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region

Identification of vascular endothelial growth factor receptor-binding protein in the venom of eastern cottonmouth: A new role of snake venom myotoxic LYS49-phospholipase A2

Functional analysis of DM64, an antimyotoxic protein with immunoglobulin-like structure from Didelphis marsupialis serum

Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: Role of heparan sulfate proteoglycans

Binding of a Naja naja venom acidic phospholipase A2 cognate complex to membrane-bound vimentin of rat L6 cells: Implications in cobra venom-induced cytotoxicity

Cell surface nucleolin interacts with and internalizes Bothrops asper Lys49 phospholipase A2 and mediates its toxic activity

Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2

The neurotoxic phospholipase A2 associates, through a non-phosphorylated binding motif, with 14-3-3 protein γ and ε isoforms

L-type voltage-dependent calcium channel is involved in the snake venom group IA secretory phospholipase A2-induced neuronal apoptosis

Pancreatic and snake venom presynaptically active phospholipases A2 inhibit nicotinic acetylcholine receptors

Neurotoxic phospholipase A2 from rattlesnake as a new ligand and new regulator of prokaryotic receptor GLIC (proton-gated ion channel from G. violaceus)

Rattlesnake phospholipase A2 increases CFTR-chloride channel current and corrects ∆F508CFTR dysfunction: Impact in cystic fibrosis

Secretory phospholipase A2-IIA upregulates HER/HER2-elicited signaling in lung cancer cells

Crystal structure of phospholipase PA2-Vb, a protease-activated receptor agonist from the Trimeresurus stejnegeri snake venom

Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1

The neurotoxic secreted phospholipase A2 from the Vipera a. ammodytes venom targets cytochrome c oxidase in neuronal mitochondria

Identification of a new high-affinity binding protein for neurotoxic phospholipases A2. Biochemical and biophysical research communications

Secreted phospholipases A2 in hereditary angioedema with C1-inhibitor deficiency

Characterization of a human coagulation factor Xa-binding site on Viperidae snake venom phospholipases A2 by affinity binding studies and molecular bioinformatics

Structure of human M-type phospholipase A2 receptor revealed by cryo-electron microscopy

Structural elements of secretory phospholipases A2 involved in the binding to M-type receptors

Fortes-Dias CL. Structural and evolutionary insights into endogenous alpha-phospholipase A2 inhibitors of Latin American pit vipers

Bee venom phospholipase A2 alleviate house dust mite-induced atopic dermatitis-like skin lesions by the CD206 mannose receptor

The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog

A model to explain the pharmacological effects of snake venom phospholipases A2

Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor

Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling

Identification of the myotoxic site of the Lys49 phospholipase A2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities

Active-site mutagenesis of a Lys49-phospholipase A2: biological and membrane-disrupting activities in the absence of catalysis

A structure-based proposal for a comprehensive myotoxic mechanism of phospholipase A2-like proteins from viperid snake venoms

Unresolved issues in the understanding of the pathogenesis of local tissue damage induced by snake venoms

Short linear motifs characterizing snake venom and mammalian phospholipases A2

ALP/Enigma PDZ-LIM domain proteins in the heart

Syntrophin proteins as Santa Claus: Role(s) in cell signal transduction

Structural and functional characterization of anticoagulant, FXa-binding Viperidae snake venom phospholipases A2

Daboxin P, a major phospholipase A2 enzyme from the Indian Daboia russelii russelii venom targets factor x and factor Xa for its anticoagulant activity

Crystal structure of isoform CBd of the basic phospholipase A2 subunit of crotoxin: Description of the structural framework of CB for interaction with protein targets

Inhibition of nicotinic acetylcholine receptors, a novel facet in the pleiotropic activities of snake venom phospholipases A2

Biophysical basis of the promiscuous binding of B-cell lymphoma protein 2 apoptotic repressor to BH3 ligands

A promiscuous intermediate underlies the evolution of LEAFY DNA binding specificity

Comparative structural studies of two natural isoforms of ammodytoxin, phospholipases A2 from Vipera ammodytes ammodytes which differ in neurotoxicity and anticoagulant activity

Identification of continuous interaction sites in PLA2-based protein complexes by peptide arrays

Presence of the M-type sPLA2 receptor on neutrophils and its role in elastase release and adhesion

Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2

Gene expression of pancreatic-type phospholipase-A2 in rat ovaries: Stimulatory action on progesterone release

Type IB secretory phospholipase A2 is contained in insulin secretory granules of pancreatic islet β-cells and is co-secreted with insulin from glucose-stimulated islets

The C-terminal region of ammodytoxins is important but not sufficient for neurotoxicity

A neurotoxic phospholipase A2 impairs yeast amphiphysin activity and reduces endocytosis

Bret Church W. Structural and functional aspects of targeting the secreted human group IIA phospholipase A2

Ammodytoxin, a secretory phospholipase A2, inhibits G2 cell-cycle arrest in the yeast Saccharomyces cerevisiae

Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner

The phospholipase A2 homologues of snake venoms: Biological activities and their possible adaptive roles

Current insights into functions of phospholipase A2 receptor in normal and cancer cells: More questions than answers

Multiple roles of phospholipase A2 during lung infection and inflammation

Protein promiscuity and its implications for biotechnology

An evolutionary biochemist's perspective on promiscuity

Snake phospholipase A2 neurotoxins enter neurons, bind specifically to mitochondria, and open their transition pores

Ultrastructural evidence for the uptake of a neurotoxic snake venom phospholipase A2 into mammalian motor nerve terminals

Rat brain cortex mitochondria release group II secretory phospholipase A2 under reduced membrane potential

Motor proteins at the mitochondria-cytoskeleton interface

Introducing intermediate filaments: From discovery to disease

Selective inhibition of human group IIA-secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes

Vimentin mediates uptake of C3 exoenzyme

The intermediate filament protein vimentin is essential for axonotrophic effects of Clostridium botulinum C3 exoenzyme

The diverse roles and dynamic rearrangement of vimentin during viral infection

Superficial vimentin mediates DENV-2 infection of vascular endothelial cells

Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization

Internalized group V secretory phospholipase A2 acts on the perinuclear membranes

New perspectives of physiological and pathological functions of nucleolin (NCL)

Nucleolin rescues TDP-43 toxicity in yeast and human cell models

Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system

Functional association of type IIA secretory phospholipase A2 with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway

Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2

Clearance of group X secretory phospholipase A2 via mouse phospholipase A2 receptor

Activation of MAP kinase cascade induced by human pancreatic phospholipase A2 in a human pancreatic cancer cell line

Nuclear location of PLA2-I in proliferative cells

A heteromeric Texas coral snake toxin targets acid-sensing ion channels to produce pain

Group IIA secretory phospholipase A2 (GIIA) mediates apoptotic death during NMDA receptor activation in rat primary cortical neurons

Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction

α7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways

sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor

Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3

Understanding the molecular mechanism underlying the presynaptic toxicity of secreted phospholipases A2: An update

Metalloproteases affecting blood coagulation, fibrinolysis and platelet aggregation from snake venoms: Definition and nomenclature of interaction sites

The C-terminal and β-wing regions of ammodytoxin A, a neurotoxic phospholipase A2 from Vipera ammodytes ammodytes, are critical for binding to factor Xa and for anticoagulant effect

Basic residues of human group IIA phospholipase A2 are important for binding to factor Xa and prothrombinase inhibition: Comparison with other mammalian secreted phospholipases A2

Two acidic, anticoagulant PLA2 isoenzymes purified from the venom of monocled cobra Naja kaouthia exhibit different potency to inhibit thrombin and factor Xa via phospholipids independent, non-enzymatic mechanism

Eicosanoid storm in infection and inflammation

Emerging role of phospholipase-derived cleavage products in regulating eosinophil activity: Focus on lysophospholipids, polyunsaturated fatty acids and eicosanoids

Emerging roles of secreted phospholipase A2 enzymes: The 3rd edition

Purification and characterization of a glycoprotein inhibitor of toxic phospholipase from Withania somnifera

Purification of a post-synaptic neurotoxic phospholipase A2 from Naja naja venom and its inhibition by a glycoprotein from Withania somnifera

Molecular details of secretory phospholipase A2 from flax (Linum usitatissimum L.) provide insight into its structure and function

PLA2R1: Expression and function in cancer

Generation of a conditional transgenic mouse model expressing human Phospholipase A2 Receptor 1

Cytotoxicity of snake venom enzymatic toxins: Phospholipase A2 and L-amino acid oxidase

A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arteriosclerosis, Thrombosis, and Vascular Biology

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

Biomarkers for epithelial-mesenchymal transitions

Secreted phospholipase A2 enzymes as therapeutic targets

Neuronal expression of vimentin in the Alzheimer's disease brain may be part of a generalized dendritic damage-response mechanism

Inflammatory action of secretory PLA2 from snake venoms. Toxins and Drug Discovery

Host response to Bothrops asper snake venom -Analysis of edema formation, inflammatory cells, and cytokine release in a mouse model

Inflammatory events induced by Lys-49 and Asp-49 phospholipases A2 isolated from Bothrops asper snake venom: role of catalytic activity

Secretory phospholipases A2 isolated from Bothrops asper and from Crotalus durissus terrificus snake venoms induce distinct mechanisms for biosynthesis of prostaglandins E2 and D2 and expression of cyclooxygenases

A catalytically-inactive snake venom Lys49 phospholipase A₂ homolog induces expression of cyclooxygenase-2 and production of prostaglandins through selected signaling pathways in macrophages

Inflammatory effects of snake venom myotoxic phospholipases A2

Articular inflammation induced by an enzymatically-inactive Lys49 phospholipase A2: activation of endogenous phospholipases contributes to the pronociceptive effect

Roles of secreted phospholipases A₂ in the mammalian immune system. Protein and peptide letters

Phospholipase A2 enzymes and the risk of atherosclerosis

Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner

Secretory PLA2-IIA: A new inflammatory factor for Alzheimer's disease

Secretory PLA2-IIA and ROS generation in peripheral mitochondria are critical for neuronal death

Secreted phospholipase A2 group IIA is a neurotoxin released by stimulated human glial cells

The role of secretory phospholipase A2 in the central nervous system and neurological diseases

This work was supported by grants from the Slovenian Research Agency, a programme grant P1-0207 (to I.K.) and a Young Researcher grant 1000-17-0106-6 (to A.I.).

The authors have declared that no competing interest exists.